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Dysregulation of the WNT and insulin-like growth fac-
tor 2 (IGF2) signaling pathways has been implicated
in sporadic and syndromic forms of adrenocortical
carcinoma (ACC). Abnormal -catenin staining and
CTNNB1 mutations are reported to be common in
both adrenocortical adenoma and ACC, whereas ele-
vated IGF2 expression is associated primarily with
ACC. To better understand the contribution of these
pathways in the tumorigenesis of ACC, we exam-
ined clinicopathological and molecular data and
used mouse models. Evaluation of adrenal tumors
from 118 adult patients demonstrated an increase
in CTNNB1 mutations and abnormal -catenin accu-
mulation in both adrenocortical adenoma and ACC.
In ACC, these features were adversely associated
with survival. Mice with stabilized -catenin exhib-
ited a temporal progression of increased adreno-
cortical hyperplasia, with subsequent microscopic
and macroscopic adenoma formation. Elevated Igf2
expression alone did not cause hyperplasia. With
the combination of stabilized -catenin and ele-
vated Igf2 expression, adrenal glands were larger,
displayed earlier onset of hyperplasia, and devel-
oped more frequent macroscopic adenomas (as
well as one carcinoma). Our results are consistentwith a model in which dysregulation of one path-
way may result in adrenal hyperplasia, but accumu-
lation of a second or multiple alterations is neces-
sary for tumorigenesis. (Am J Pathol 2012, 181:1017–
1033; http://dx.doi.org/10.1016/j.ajpath.2012.05.026)
Adrenocortical tumors are fairly common, occurring in
approximately 3% to 10% of the population.1 Frequently,
adrenocortical tumors are discovered as part of an unre-
lated imaging examination, and most are benign adreno-
cortical adenomas (ACAs). In contrast, adrenocortical
carcinomas (ACCs) are rare, with an annual incidence of
1 to 2 per million of the U.S. population.1,2 Unfortunately,
a substantial number of ACC patients present with ad-
vanced disease, including 30% to 40% with clear evi-
dence of metastatic disease, and the available treat-
ments for advanced disease are rarely curative. The
overall 5-year survival rate has been reported to range
from 10% to 40%.3–5
Although most ACCs arise sporadically, certain ge-
netic syndromes have been associated with an increased
incidence of ACC. Familial adenomatous polyposis (FAP)
patients have a mutated adenomatous polyposis coli
gene (APC) and higher rates of a variety of cancers, most
notably colorectal cancer. ACC is also thought to occur at
a higher rate in these patients, although the statistical
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tion.6 APC is a component of the cadherin-associated
protein  1 (CTNNB1; commonly known as -catenin)
destruction complex, which, in the absence of WNT
(wingless-type MMTV integration) signaling, helps facili-
tate the phosphorylation of -catenin, targeting it for deg-
radation. The presence of WNT signaling or decreased
expression/mutation of APC results in stabilization and nu-
clear translocation of active -catenin. In the nucleus,
-catenin acts as a transcriptional cofactor with members of
the T-cell factor/lymphoid enhancer factor (TCF/LEF) family
to regulate target gene expression.7
WNT signaling has been shown to play an important role
in organ development and has been implicated as a caus-
ative factor in a variety of cancers.7 In the adrenal gland, the
Wnt pathway is required for normal gland formation, and
adrenocortical cell-specific knock out of Ctnnb1 in mice
results in adrenal gland aplasia.8 A number of tumor profil-
ing studies have revealed abnormalities in -catenin in both
ACA and ACC.9–12 Here, we present data from a cohort of
118 adult patients with ACA or ACC, of whom 24% and
30%, respectively, displayed cytoplasmic and/or nuclear
-catenin staining, compared with the membranous stain-
ing found in the normal adrenal cortex. Approximately 20%
of the patients in the cohort had exon 3 CTNNB1mutations,
which alter the consensus site for glycogen synthase kinase
3 (GSK3)-mediated phosphorylation and thus abrogate
-catenin degradation.13–15
Insulin-like growth factor 2 (IGF2) is a critical growth
factor in the development of many organ systems, including
the adrenal cortex. Reciprocal imprinting defects of the
11p15.5 locus result in either Silver-Russell syndrome or
Beckwith-Wiedemann syndrome (BWS). Silver-Russell syn-
drome is characterized by elevated expression of H19, de-
creased expression of IGF2, hypomethylation of the imprint-
ing control region, and growth retardation.16 BWS is
characterized by elevated expression of IGF2, hypermeth-
ylation of the imprinting control region, and organ over-
growth.17 BWS patients have, among other manifestations,
an increased rate of ACC.17 IGF2 is a mitogen that acts by
binding the cell surface receptor, IGF-1R, resulting in its
autophosphorylation and a downstream signaling cascade
that engages a number of cellular processes, including
cell-cycle progression and proliferation.18 Large-scale
gene expression studies from our research group and from
others have revealed that IGF2 expression is dramatically
up-regulated in at least 80% of sporadic ACCs, compared
with either ACA or normal adrenal tissue.19–23
To examine the potential interaction of Wnt and Igf2
signaling pathways in ACC, we developed mutant mouse
models in which these pathways are perturbed. Mice
lacking Apc specifically in the adrenal cortex displayed
age-dependent adrenocortical hyperplasia as micro-
scopic to macroscopic adenomas. Adrenal cortex-spe-
cific loss of imprinting at the Igf2/H19 region in mice
results in elevated Igf2 expression and minor adrenocor-
tical dysplasia, but no actual hyperplasia. When the Apc
and Igf2/H19 alterations are combined in the adrenal
cortex, mice exhibited earlier signs of adrenocortical hy-
perplasia, earlier and more severe microscopic and mac-
roscopic adenomas, and cancer formation. Our presentresults, along with data from other genetic profiling stud-
ies, as discussed below, suggest that multiple genetic
aberrations are required for ACC development.
Materials and Methods
Frozen Human Tissues, Histopathology, and
RNA isolation
Frozen tumor samples from the 55 patients in the University
of Michigan Health System (UMHS) cohort were either ob-
tained from the Cooperative Human Tissue Network (CHTN)
or derived from UMHS surgical specimens procured by the
Tissue Procurement Service of the University of Michigan
Comprehensive Cancer Center. Histopathology and clinical
and pathological features of the tissues (including stage,
grade, and mitotic rate) were as described previously.19
Samples from the University of São Paulo (USP) cohort
included frozen tissues from 63 adrenocortical tumors that
were used for mRNA isolation. In the USP cohort, 27 of the
63 tumors were classified as carcinomas according to
Weiss scoring criteria24–26 (score 2). All human data that
contributed to analysis of patient prognosis (including mi-
totic rate, stage, grade, hormone secretion, and -catenin
status) are available as part of our Gene Expression Omni-
bus (GEO) series deposited with the National Center for
Biotechnology Information (accession no. GSE33371 at
http://www.ncbi.nlm.nih.gov).
Analysis of Human RNA Samples
Microarray data have been described previously.19 The
raw array data (.CEL files) and the data set with the
statistical tests used to select for differentially expressed
genes have been deposited in the GEO database
(GSE33371).27 Probe-set annotations were updated from
the Affymetrix website (version na32, June 2011 edition).
Quantitative real-time PCR (qPCR) of samples from the
USP cohort was performed as described previously.28
Gene expression was analyzed using TaqMan expres-
sion arrays: Hs01005963_m1 for detection of IGF2 and
4326315E for ACTB (-actin) as a control.
Tissue Microarray of Human Samples and
Analysis
UMHS Cohort
An adrenal tissue array of samples, designated Adren-
alTMA3, was constructed as described previously.19 Im-
munohistochemistry for -catenin was performed using
this AdrenalTMA3 as described previously.29 Because
staining patterns were consistent throughout the ACC
tissue sections, -catenin immunoreactivity was scored
in a simple dichotomous manner by evaluating the tumor
cells for membranous staining versus cytoplasmic and/or
nuclear immunolocalization.
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TMA blocks were prepared from representative tumor
areas as described previously,28 and were evaluated by
IHC with mouse anti-human -catenin antibody (1:200;
M3539; DakoCytomation, Carpinteria, CA). Two investi-
gators without knowledge of the clinical data indepen-
dently evaluated -catenin staining. Immunoreactivity for
-catenin was evaluated in both nucleus and cytoplasm.
Each sample was scored as described previously.10,11
Genomic Mutational Analysis of the
CTNNB1 Gene
Somatic mutations of exon 3 of the CTNNB1 gene were
screened in UMHS tumor samples by DNA sequencing of
exon 3, as described previously.29 USP tumor samples of
from adult patients (24 adenomas and 18 carcinomas)
were also screened for somatic mutations of exon 3 of the
CTNNB1 gene by automatic sequencing. Briefly, primers
were designed to amplify exon 3 and the flanking intronic
sequences of the -catenin gene (CTNNB1): 5=-TGGGT-
CATATCACAGATTCTTTTTTT-3= and 5=-TCAAAACTG-
CATTCTGACTTTCA-3=. PCR amplification used Taq DNA
polymerase (Promega, Madison, WI). The amplified prod-
ucts were directly sequenced on an ABI 7000 sequence
detection system (Life Technologies-Applied Biosys-
tems, Foster City, CA). Mutations were verified in both
sense and anti-sense directions.
Mouse Models
Steroidogenic factor 1 (Sf1)-Cre transgenic mice were
obtained from Keith Parker (University of Texas-South-
western, Dallas, TX).30 Sf1 is also known as nuclear re-
ceptor subfamily 5, group A member 1 (encoded by
Nr5a1). The Sf1-Cre single-copy transgene targets low
levels of expression of Cre recombinase to the urogenital
ridge by E10.0 and activates a Cre-dependent reporter
gene stochastically throughout the adrenal cortex.8,30 Mice
carrying floxed exon 14 of the Apc allele31 (ApcloxP/loxP)
were obtained from Bart Williams (Van Andel Institute,
Grand Rapids, MI). In mice harboring two floxed Apc
alleles and the Sf1-Cre transgenes, Cre recombination
results in a frameshift mutation generating a null product
in Sf1-expressing tissues, including the adrenal cortex
[APC knock-out (KO)] (see Supplemental Figure S1A at
http://ajp.amjpathol.org). Mice carrying the floxed Ctnnb1
Table 1. Genotyping of Mouse Models
Transgene Primer
Sf1-Cre Fwd 5=-CAATTTACTGACCGTACAC
Rev 5=-AGCTGGCCCAAATGTTGCT
ApcloxP/loxP Fwd 5=-GTTCTGTATCATGGAAAGA
Rev 5=-CACTCAAAACGCTTTTGAG
Ctnnb1tm2kem Fwd 5=-AAGGTAGAGTGATGAAAGT
Rev 5=-CACCATGTCCTCTGTCTAT
H19lxDMD/lxDMD Fwd 5=-CACACAAAGGATTCTTTGC
Rev 5=-TGCAAGGAGACCATGCCTATA, annealing temperature; WT, wild type.gene (Ctnnb1tm2kem) were purchased from the Jackson
Laboratory (Bar Harbor, ME). This cistron contains loxP
sites flanking exons 2 to 6 and produces an inactive
-catenin product on Cre-mediated excision32 (BCAT
KO) (see Supplemental Figure S1B at http://ajp.
amjpathol.org). Some studies involved mice that were the
result of crossing APC KO mice with BCAT KO mice
(APC-BCAT KO) (see Supplemental Figure S1C at http://
ajp.amjpathol.org). Mice with loxP sites flanking the Igf2/
H19 imprinting control region (differentially methylated
domain, or DMD; H19lxDMD/lxDMD) were a kind gift from
Marisa Bartolomei (University of Pennsylvania, Philadel-
phia, PA).33 On crossing a female H19lxDMD/lxDMD mouse
with a male Sf1-Cre mouse, Cre recombination in Sf1-
expressing tissues results in loss of imprinting at the
maternal Igf2/H19 locus and expression of Igf2 from both
maternal and paternal alleles (H19DMD) (see Supple-
mental Figure S2A at http://ajp.amjpathol.org). Combined
loss of Apc and Igf2/H19 imprinting was achieved by
breeding Apcfloxed/floxed mice with H19lxDMD/lxDMD mice
(APC KO-H19DMD) (see Supplemental Figure S2B at
http://ajp.amjpathol.org). Genotyping protocols for the
mouse models are given in Table 1. After harvest of
tissues from the animals, both adrenals were weighed;
the left adrenal was processed for immunohistochemistry
and the right adrenal was flash-frozen for biochemical
analysis. In some instances in which macroadenomas
were present, tumors were cut in half to allow for immu-
nohistochemical and biochemical analyses of the same
tissue.
Immunoblot Analysis of Mouse Adrenal Lysates
Protein lysates were prepared from mouse adrenal
glands and analyzed by immunoblotting as described
previously.34 We used the following primary antibodies
directed against specific proteins: total -catenin
(610154; BD Biosciences, San Jose, CA), proliferating
cellular nuclear antigen (PCNA; sc56, Santa Cruz Bio-
technology, Santa Cruz, CA), Dax1 [dosage-sensitive sex
reversal, adrenal hypoplasia critical region on chromo-
some X, gene 1; also known as nuclear receptor subfam-
ily 0 group B member 1; encoded by Nr0b1); kindly
provided by Enzo Lalli, Institute of Molecular and Cellular
Pharmacology, Valbonne, France], total Akt (thymoma
viral proto-oncogene 1; 9272, Cell Signaling Technology,
Danvers, MA), phosphorylated Akt at Ser473 (4051S; Cell
Signaling Technology), and -actin (A5441; Sigma-Al-
TA (°C) Product size (bp)
61 WT: no band
Cre: 280
GG-3= 55 WT: 320
AT-3= floxed: 370
3= 60 WT: 300
floxed: 400
G-3= 58 WT: 297
G-3= floxed: 347-3=
G-3=
TAGGT
GGTTG
TGTT-
TC-3=
AGAGA
TTCTT
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horseradish peroxidase-conjugated (Roche, Indianapo-
lis, IN) or IRdye conjugated (LI-COR Biosciences, Lin-
coln, NE); for detection, we used West Dura enhanced
chemiluminescence reagent (Pierce; Thermo Fisher Sci-
entific, Rockford, IL) and autoradiography or a LI-COR
Odyssey infrared system.
Analysis of Mouse Adrenal Gland Histology and
Immunohistochemistry
Adrenal glands were collected at 6, 15, 30, 45, and 45
weeks of age and were fixed, processed, and sectioned
as described previously.8 The following antibodies were
used: Dax1 (generously provided by Ken Morohashi,
Kyushu University, Japan35), 20-Hsd (20-hydroxy-
steroid dehydrogenase; generously provided by Yacob
Weinstein, Ben Gurion University, Israel), -catenin
(610154 from BD Biosciences, or sc7199 from Santa
Cruz Biotechnology, Santa Cruz, CA), tyrosine hydroxy-
lase (TH; MAB318; Millipore, Billerica, MA) and Sf1 (cus-
tom anti-Sf1 prepared by Proteintech Group, Inc, Chi-
cago, IL). IHC was performed using a Vectastain ABC
(avidin/biotinylated enzyme complex) kit or a Mouse on
Mouse (M.O.M.) kit according to the manufacturer’s pro-
tocol (Vector Laboratories, Burlingame, CA). Tissue sec-
tions were incubated at 4°C overnight with primary anti-
body, washed, and incubated with secondary antibodies
provided with the Vectastain ABC kit or M.O.M kit. Anti-
gen was detected through the use of SIGMAFAST 3,3=-
diaminobenzidine tablets (D4168, Sigma-Aldrich). Sec-
ondary antibodies used for immunofluorescence were
DyLight dyes 488 and 549, goat anti-mouse or goat anti-
rabbit from Jackson ImmunoResearch (West Grove, PA).
Sections were analyzed by normal light or fluorescent
microscopy. Ki-67 detection (ab16667; Abcam) in mouse
adrenals was conducted by the Pathology Cores for An-
imal Research at the University of Michigan, Unit for Lab-
oratory Animal Medicine.
Analysis of Mouse RNA Samples
Total adrenal gland mRNA was prepared and analyzed by
qPCR as described previously.8 Primer sequences were as
follows: Axin2: 5=-GCAGGAGCCTCACCCTTC-3=to 5=-TGC-
CAGTTTCTTTGGCTCTT-3=; -actin: 5=-ACCCGCCAC-
CAGTTCGCCAT-3= to 5=-TACAGCCCGGGAGCATCGT-3=;
Igf2: 5=-CGCTTCAGTTTGTCTGTTCG-3= to 5=-GCAG-
CACTCTTCCACGATG-3=; and Lef1 (lymphoid enhancer
binding factor 1): 5=-CTGAAATCCCCACCTTCTACC-3= to
5=-TGGGATAAACAGGCTGACCT-3=. All primers were vali-
dated.36
Human and Animal Research Statements
The Endocrine Database of the University of Michigan
Endocrine Bank securely joins clinical data about a pa-
tient’s course of disease, pathology data, and outcome of
treatment. The database is Institutional Review Board-
approved as a repository of retrospectively gathered pa-tient data behind the UMHS firewall and under control of
a small research team. Each research project that in-
tends to query these data to address a research hypoth-
esis undergoes a separate Institutional Review Board
approval process based on its own merits and risks, as
did the present study. Studies from the University of São
Paulo were approved by the ethics committee of Clinical
Hospital, São Paulo, Brazil, and informed consent was
obtained from all patients and/or responsible represen-
tatives.
All experiments involving mice were performed in ac-
cordance with an institutionally approved protocol under
the auspices of the University of Michigan Committee on
Use and Care of Animals. Veterinary care was provided
by the Unit for Laboratory Animal Medicine staff at the
University of Michigan based on standards in the current
Guide for Care and Use of Laboratory Animals, the Animal
Welfare Act Regulations, and the Public Health Service
Policy on Humane Care and Use of Laboratory Animals.
Results
Abnormal -Catenin Staining and CTNNB1
Mutations Correlate with Poor Prognosis in
Human ACCs
The present study population comprises a combined co-
hort of 118 adult adrenal tumor samples from the UMHS
and the USP. Of these samples, 58 were classified as
adenomas (22 UMHS and 36 USP; Weiss score  u2)
and 60 as carcinomas (33 UMHS and 27 USP; Weiss
score  2). Previous studies have demonstrated abnor-
mal cytoplasmic and nuclear accumulation of -catenin
in ACAs and ACCs.9,12,37 We therefore evaluated the
status of WNT pathway activation by IHC for -catenin in
tumors from this cohort, using tissue arrays. Representa-
tive images from IHC analysis for membranous -catenin
and abnormal nuclear -catenin staining are presented in
Figure 1A. Abnormal cytoplasmic and/or nuclear -catenin
immunoreactivity was observed in 24.1% (14/58) of the
ACAs and 30% (18/60) of the ACCs.
DNA sequencing of exon 3 of the CTNNB1 gene was
performed for 46 ACAs and 31 ACCs, revealing muta-
tions in 21.7% and 22.6% of the cases, respectively.
Mutations observed included those previously found in
ACC, which result in serine to proline (S45P) and proline
to alanine (P44A), and a change at aspartic acid
32.9,12,38 In addition, we found missense mutations re-
sponsible for amino acid changes, including serine to
cysteine (S37C), glycine to glutamine (G34E), leucine to
proline (L46P), or aspartic acid to glycine (D32G). Dele-
tions within exon 3 were also observed (S45del, 41del 5,
43del 8, and 44del1).
In a recent study of both French and German patients,
Gaujoux et al12 found that WNT pathway activation as
assessed by -catenin immunohistochemistry was asso-
ciated with survival. To confirm and extend those results,
we performed Kaplan-Meier analysis using data from a
total of 50 patients with follow-up data available (23
UMHS and 27 USP), and found that ACC patients with
IGF2 and -Catenin in ACC 1021
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poorer survival than patients with tumors displaying
membranous -catenin (P  0.006 log-rank test, UMHS
and USP combined; Figure 1, B and C). Moreover, al-
though -catenin status in ACCs was not associated with
McFarlane stage, it was associated with high-grade dis-
ease as assessed by mitotic rate 20 and analyzed as
log2-transformed data (Table 2). In the UMHS cohort, 8/8
tumors with nuclear -catenin staining were high grade,
compared with only 9/15 hours without abnormal
-catenin (P 0.058 two-sided Fisher’s exact test); in the
USP cohort, only 1/5 tumors with nuclear -catenin stain-
ing were high grade, whereas none of the 22 tumors
without abnormal -catenin were high grade (Table 3).
The -catenin status of the tumors was significantly as-
sociated with prognosis in ACC in univariable models, as
others have reported.12 In multivariate Cox models, how-
ever, using stage and grade (mitotic rate), we found
including -catenin status did not significantly improve
survival prediction (Table 2). The Gaujoux et al12 group
that reported independent predictive power for -catenin
did examine mitotic rate, but did not incorporate it as one
of the clinical measures in their models. Because abnor-
mal -catenin status is preferentially present in ACC with
high mitotic rates (high-grade ACC), it is not surprising
that the predictive power of -catenin is diminished when
tumor grade is considered.39 Thus, our results confirm
that CTNNB1 mutations and abnormal -catenin localiza-
tion are found with similar frequency in ACA and ACCs.
Furthermore in ACC, abnormal -catenin is associated
with increased mitotic rates and poor prognosis.
Studies in mice and humans have suggested an asso-
ciation between abnormal -catenin expression and hy-
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Figure 1. Abnormal -catenin localization correlates with poor prognosis in
humans. A: Immunohistochemistry in ACC showing typical membranous
-catenin or nuclear -catenin. B: Kaplan-Meier analysis of the UMHS cohort
indicated that patients with membranous -catenin staining (n  15) had a
better survival rate than those with nuclear -catenin staining (n  8; P 
0.06 log-rank test). C: Kaplan-Meier analysis of the USP cohort indicated that
patients with membranous -catenin staining (n  22) had a better survival
rate than those with nuclear -catenin staining (n  5; P  0.09 log-rank
test).peraldosteronism.40,41 Other studies, however, have notfound a clear correlation between tumor hormone pro-
duction and -catenin status.12,37 In the UMHS cohort, of
the 22 ACAs with hormone data available, 8 tumors dis-
played abnormal -catenin staining, and 5 of these were
found to be non-hormone secreting (P  0.01 Fisher’s
exact test; Table 4). In contrast, 12 of 29 ACCs in the
UMHS cohort displayed abnormal -catenin staining,
and 11 of these were hormone-producing (P  0.02).
These associations were not found to be significant in the
USP cohort. Of 36 ACAs in the USP cohort with hormone
data available, 10 had abnormal -catenin, and 6 of
these 10 were hormone-producing (P 0.23; Table 4). Of
the 27 ACCs in the USP cohort, 4 of 5 tumors with abnor-
mal -catenin were hormone-producing (P  0.47).
These data suggest variability in the UMHS versus USP
patient cohorts or in the clinical diagnosis of hormone
excess in each population. It is intriguing that -catenin
mutations and hormone production have been shown
independently to predict worse prognosis in ACC.42
Abnormal -Catenin Status Correlates with
Changes in Gene Expression and an
Enrichment of Up-Regulated LEF1 Target
Genes
To examine global changes in gene expression, we used
our previous array data from the GEO series (GSE33371;
formerly GSE10927) consisting of mRNA abundance as-
says of the 33 ACCs, 22 ACAs, and 10 normal adrenal
cortex samples from the UMHS cohort run on HG-
U133_Plus_2 arrays, which hold 54,675 probe sets.19
Both ACA and ACC samples were divided into two
groups, based on -catenin status: one group with cyto-
plasmic/nuclear staining or CTNNB1 mutations (Bcat)
and the other with normal membranous staining and no
CTNNB1 mutations (Bcat). Thus, including normal ad-
renal cortex samples, we had five groups (normal,
Table 2. Multivariable Cox Proportional Hazard Models for
Patient Survival
Cohort and effect
P value
(Wald test)
Relative Risk
(95% CI)
UMHS cohort
-catenin, nuclear
vs membranous
0.220 1.89 (0.69–5.21)
Mitotic rate, log2-
transformed*
0.020 1.84 (1.10–3.07)
Stage IIIIV vs III 0.049 2.96 (1.00–8.70)
USP cohort
-catenin, nuclear
vs membranous
0.92 1.07 (0.30–3.79)
Mitotic rate, log2-
transformed*
0.21 1.36 (0.84–2.20)
Stage IIIIV vs III 0.0033 8.06 (2.00–32.36)
Combined
-catenin, nuclear
vs membranous
0.29 1.54 (0.70–3.41)
Mitotic rate, log2-
transformed*
0.0016 1.55 (1.18–2.03)
Stage IIIIV vs III 0.00085 4.14 (1.80–9.52)*Mitotic rates of 5 set equal to 5.
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Bcat, n  8; and ACA Bcat n  14) to which we fit
analysis of variance models with separate means for
each group. One ACC, for which no -catenin analysis
was performed, was excluded. Using pairwise contrasts
between Bcat versus Bcat ACCs, we obtained 4559
probe sets corresponding to transcripts that differed sig-
nificantly (P  0.01). A similar comparison in ACAs re-
vealed that signal from only 763 probe sets differed sig-
nificantly (P  0.01). In both cases, we expected
approximately 547 (ie, 54,675  0.01) P values this small
by chance, indicating that only approximately 12% of the
probe sets representing transcripts whose expression
levels appear significantly up or down in ACC Bcat are
false positives. Of the probe sets with P 0.01, we further
selected only those in the ACC comparison with average
differences of at least 1.5-fold and thereby obtained a list
of probe sets representing 1230 increased and 1087 de-
creased transcripts (see Supplemental Table S1 at http://
ajp.amjpathol.org). Compared with ACC, -catenin status
in our ACA samples corresponded to fewer transcripts
that were changed more that 1.5-fold and with P  0.01
(278 increased and 211 decreased). In addition, there
was minimal overlap in similarly affected transcripts in
ACC and ACA (a total of 14 probe sets). In fact, the probe
sets were significantly negatively associated; there were
more transcripts for which abnormal -catenin correlated
with an increase in ACC and a decrease in ACA and vice
versa (a total of 16 and 21 probe sets, respectively),
compared with transcripts that were regulated in the
Table 3. Association of -Catenin status with Stage and Grade
Cohort
Nuclear -catenin w
stage or grade
Association of -catenin and stage
UMHS cohort 4/8
USP cohort 3/5
Combined 7/13
Association of -catenin and grade
UMHS cohort 8/8
USP cohort 1/5
Combined 9/13
*Two-sided Fisher’s exact test.
Table 4. Correlation of -catenin status to Hormone Secretion in
UMHS cohort
Membranous
-catenin
Nuc
Adrenocortical adenomas
Nonfunctional 1
Functional 13
Total 14
Adrenocortical carcinomas
Nonfunctional 9
Functional 8
Total 17
*Abnormal -catenin status is correlated with nonsecretion; P  0.01
†Abnormal -catenin status is not correlated with secretion; P  0.23
‡Abnormal -catenin status is correlated with secretion; P  0.02, Fisher’s ex
§Abnormal -catenin status is not correlated with secretion; P  0.47, Fishersame direction in both ACC and ACA (see Supplemental
Table S1 at http://ajp.amjpathol.org). The full array data
and results for this and other statistical tests are available
in the GEO database (GSE33371).
A subset of the most profound differences (fold
change  2.5, P  0.0001) is presented in Figure 2.
Transcripts for the -catenin target genes LEF1, axin 2
(AXIN2), and isthmin 1 homolog (ISM1) are increased in
ACC with abnormal -catenin status. Surprisingly,
these targets are not increased in Bcat ACA. Certain
other transcripts are decreased in Bcat ACC, includ-
ing the met proto-oncogene (MET), which has been
reported to be associated with -catenin in a variety of
cancers.43–45 This evaluation also revealed genes
whose expression levels differ (generally as a de-
crease) specifically in ACC with normal -catenin sta-
tus (Bcat). This group includes nephroblastoma over-
expressed (NOV), also known as connective tissue
growth factor 3 (CCN3), an apoptotic factor that is also
decreased in pediatric ACC.46,47
Altered gene expression in Bcat ACC may be ex-
pected to reflect changes in specific cellular processes.
To examine this possibility, we performed enrichment
testing using several publicly available sets of gene lists.
After removing redundancy in the 1230 up and 1087
down probe sets, we obtained lists of 678 up and 742
down distinct transcripts (see Supplemental Table S2 at
http://ajp.amjpathol.org). Genes with Gene Ontology (GO)
terms for cell division and cell adhesion were significantly
over-represented in the list of genes whose expression
h Membranous -catenin with high
stage or grade (n/N) P value*
7/15 1.0
8/22 0.37
15/37 0.52
9/15 0.058
0/22 0.19
9/37 0.007
and ACCs
USP cohort (no.)
toplasmic
tenin
Membranous
-catenin
Nuclear/cytoplasmic
-catenin
* 5 4
21 6†
26 10
2 1
‡ 20 4§
22 5
s exact test.
’s exact test.ith hig
(n/N)ACAs
(no.)
lear/cy
-ca
5
3
8
1
11
12
, Fisher’
, Fisheract test.
’s exact test.
Cs, exce
n (ratio
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AJP September 2012, Vol. 181, No. 3was elevated in Bcat ACCs, compared with Bcat,
whereas genes involved in antigen processing and
immune response were under-represented. Tran-
scripts increased in Bcat ACC were enriched for
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways relating to the cell cycle, focal adhesion, and
p53, WNT, and TGF- signaling, whereas transcripts
decreased in Bcat ACC were enriched for pathways
involving the immune system. Over-representation of
genes involved in cell division and cell cycle in both
enrichment tests suggests an increased proliferative
capacity in Bcat ACC, compared with Bcat ACC. We
also tested lists of genes in the Molecular Signatures
Database (MSigDB; http://w/broadinstitute.org/gsea/
msigdb/index.jsp) curating cis-regulatory DNA motifs
and found up-regulated genes most enriched for LEF1
Ratio to the median of ACCs, except the last 3, where it i
1 2 41/21/4
Normal
Bcat- BBcat+
ACA
Figure 2. Gene expression differences between ACCs with normal memb
An analysis of variance model fit to the five groups (normal, ACC Bcat, A
ACCs. Probe sets that yielded P  0.0001 and an average fold change o
identifiers. Only the probe set with the smallest P value for a gene is sh
of -catenin exon 3. Data are expressed as the ratio to the median of AC
the highest expression (ratio 4) and green indicates the lowest expressioand NFAT (nuclear factor of activated T cells) bindingsites.48 Two DNA motifs for the LEF1 transcription fac-
tor were particularly significant (P  1010; see Sup-
plemental Table S2 at http://ajp.amjpathol.org). From
these lists, selected genes were identified (those that
yielded P  0.01 and an average expression increase
of at least 1.5-fold in a comparison of Bcat ACCs with
Bcat ACCs), representing transcripts up-regulated in
Bcat ACC (see Supplemental Figure S3 at http://
ajp.amjpathol.org).
These findings demonstrate that abnormal accumu-
lation of -catenin results in relatively few changes in
the transcriptome of ACAs. In contrast, -catenin sta-
tus in ACC correlates with enhanced proliferative
potential and an altered gene signature rich in TCF/LEF
target genes, suggesting that nuclear -catenin is tran-
scriptionally active and potentially contributing to the
an of all samples.
Gene 
Symbol
DLC1
FAP
CTHRC1
COL5A2
EPHA4
PLEKHG4
C9orf84
COL11A1
SOX8
COL9A3
PDE7B
GATA3
NRXN2
TMPRSS3
UST
ISM1
KLHL14
LOC642891
MUCL1
KIF16B
NOSTRIN
NPAS2
PLCL2
FARP1
PDE2A
C8orf84
LEF1
UGCG
AXIN2
ZNF521
DAB2
CIB4
ABCB4
TNFSF4
PCOLCE
CHL1
ID2
ITGA2
DAAM2
PEG10
KCNK3
RIMS2
NOV
ZBTB7C
APCDD1
TIMP3
RNF43
LAMC3
PSD3
ETV5
ITGA9
LIFR
HSD3B1
SLC27A2
EMB
FGL2
ACTR3C
HLA-DPA1
HLA-DRB1
MS4A7
ANO5
ABCA3
RRAD
NLRC5
CXXC5
SHISA3
HCP5
ZDHHC14
CALB2
SEL1L3
MET
IGF2
H19
CDKN1C
  P-
value
4.5E-06
1.3E-05
2.1E-05
8.9E-05
8.2E-05
2.0E-05
1.9E-06
3.7E-06
6.4E-05
6.5E-06
7.6E-05
1.4E-05
2.0E-08
9.2E-08
1.3E-06
3.9E-09
3.7E-05
6.1E-05
1.3E-05
2.3E-05
8.0E-06
1.9E-05
5.4E-06
9.1E-05
1.8E-07
6.6E-05
1.7E-05
2.2E-06
1.8E-06
7.0E-05
4.1E-06
5.1E-07
2.9E-07
5.2E-06
6.2E-05
6.0E-07
3.5E-05
4.5E-07
3.3E-05
2.1E-07
4.0E-06
4.0E-05
7.3E-07
1.3E-06
4.9E-08
1.3E-05
3.1E-06
1.8E-05
5.3E-05
4.2E-05
1.4E-05
3.8E-05
9.8E-05
3.7E-05
2.4E-06
2.8E-05
1.5E-05
7.9E-05
5.8E-05
2.0E-05
6.3E-07
1.9E-05
9.5E-05
4.5E-05
7.6E-05
2.7E-06
6.4E-06
3.4E-05
1.1E-05
5.6E-06
1.1E-05
0.84
0.41
0.22
  Fold-
change
    2.64
    2.96
    3.78
    2.51
    2.92
    2.77
    8.13
    3.21
    3.87
    3.41
    2.77
    2.68
    3.67
    2.89
    2.83
  11.56
    2.68
    2.59
    5.60
    2.81
    4.31
    2.51
    3.35
    3.51
    7.39
    4.00
    4.35
    3.04
    2.67
    2.73
    3.16
    2.52
    9.24
    3.74
    8.81
    6.17
    2.98
    2.98
    3.37
    4.08
    3.07
    3.10
    7.58
    3.28
    5.94
    3.64
    2.95
    3.50
    3.04
    2.50
    2.61
    2.65
    3.04
    0.29
    0.19
    0.38
    0.39
    0.39
    0.33
    0.29
    0.36
    0.32
    0.34
    0.39
    0.36
    0.23
    0.27
    0.36
    0.18
    0.25
    0.34
    1.12
    1.47
    1.46
   Probe 
      Set 
220512_at
209955_s_at
225681_at
221730_at
206114_at
228171_s_at
233504_at
229271_x_at
226913_s_at
204724_s_at
230109_at
209602_s_at
209982_s_at
223949_at
205138_s_at
235182_at
228377_at
243432_at
1553602_at
232083_at
226992_at
39549_at
213309_at
239246_at
204134_at
235209_at
221558_s_at
204881_s_at
222696_at
226676_at
240873_x_at
236378_at
207819_s_at
207426_s_at
202465_at
204591_at
213931_at
205032_at
212793_at
212094_at
235108_at
229823_at
214321_at
227782_at
225016_at
201148_s_at
218704_at
219407_s_at
218613_at
203349_s_at
227297_at
225575_at
215665_at
205768_s_at
226789_at
227265_at
223874_at
211990_at
208306_x_at
223344_s_at
229313_at
204343_at
204803_s_at
226474_at
224516_s_at
229485_x_at
206082_at
219247_s_at
205428_s_at
212314_at
203510_at
210881_s_at
224646_x_at
213182_x_at
Bcat+
CC
-catenin (Bcat) versus cytoplasmic/nuclear -catenin staining (Bcat).
t, ACA Bcat, and ACA Bcat) was used to compare Bcat versus Bcat
st 2.5 were selected, and reduced to those annotated with Entrez gene
at ACAs were those with either -catenin nuclear staining or mutation
pt that in the last three rows the median is for all samples. Red indicates
1/4).s medi
cat-
A
ranous
CC Bca
f at lea
own. Bcmarkedly worse prognosis.
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AJP September 2012, Vol. 181, No. 3Conditional Knock-Out of Apc Causes
Stabilization of -Catenin and Aberrant
Expression of Adrenocortical Markers
in Mice
To achieve -catenin stabilization in the adrenal cortex,
we modeled adrenocortical tumors that occur in FAP
patients and in some sporadic ACCs through the use of
conditional knock out of the Apc gene.12,31 Previous
studies have evaluated mouse models with mutations
in exon 3 of Ctnnb1 in the adrenal cortex.40 Both ap-
proaches result in stabilization of -catenin and mimic
overactivation of Wnt signaling. To knock out Apc in
only the steroidogenic tissues (adrenal cortex and
gonads), our studies used the Sf1-Cre stochastic
driver.8,30 This Cre driver, which has only one copy of
the Cre transgene, has been shown to lead to incom-
plete recombination in the adrenal cortex; in contrast,
the Sf1-Cre complete driver has five copies of the Cre
transgene and leads to recombination throughout the
entire adrenal cortex.8,30 We opted to use the stochas-
tic driver, because it more closely resembles the spo-
radic nature of ACC formation in humans. Indeed, use
of the Sf1-Cre complete driver to eliminate Apc expres-
sion leads to improper development of the adrenal
gland, resulting in severely hypoplastic adrenals,
which would confound any studies looking at tumor
formation (see Supplemental Figure S4 at http://
ajp.amjpathol.org).
Conditional knock out of exon 14 of the Apc gene was
achieved by crossing Sf1-Cre stochastic transgenic mice
with mice harboring floxed Apc to produce progeny with
the Sf1-Cre/ApcloxP/loxP genotype,30,31 here termed APC
KO (see Supplemental Figure S1A at http://ajp.amjpathol.
org). APC KO mice have elevated levels of -catenin, as
confirmed by immunoblot analysis (Figure 3A). In addi-
tion, examination of mRNA levels revealed an approxi-
mately twofold increase in the -catenin target genes
Axin2 and Lef1 (P 0.018 and P 0.042, respectively) in
APC KO adrenal glands (n 4), compared with the mean
of Cre wild-type (WT) controls (n  4) (Figure 3B). The
APC KO adrenal glands also exhibited increased levels
of PCNA, suggesting that there are more cells undergo-
ing S-phase (Figure 3A).
Histological analysis of adrenal glands from 15-
week-old APC KO mice was compared with Cre WT
adrenal glands of the same age (Figure 3C). Organi-
zation of the cortex and the medulla is preserved, but
aberrant cortical cells are found intermingled with cells
of the adrenal medulla in the inner region of the gland
(H&E staining in Figure 3C). These aberrant cells in the
inner region express the essential nuclear receptor Sf1
and lack expression of TH. Rather, the TH-positive
medullary cells, which normally fill the entire central
portion of the adrenal gland, appear as patches sur-
rounded by Sf1-positive cells (Figure 3C). At higher
magnification, the immunofluorescent costaining
clearly distinguishes the aberrant cells from the med-
ullary cells (Figure 3D). In the WT adrenal, TH-express-
ing cells with membranous -catenin fill the medullary0
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Figure 3. Conditional knock out of Apc in mice results in an increase in
activated -catenin and aberrant expression of cortical markers. A: Immunoblot
analysis of whole adrenal protein lysates from 15-week-old WT (Cre controls)
or APC KO mice. Whole adrenal lysates were prepared from individual mice,
and immunoblot analysis was performed using 10 g protein. Membranes were
probed with antibodies against -catenin, PCNA, and Dax1, with -actin as a
loading control. Blots shown are representative of four replicates (four different
mice of each genotype) with similar results. B: Analysis of mRNA expression
from 15-week-old WT and APC KO mice. Total RNA from whole adrenal glands
was evaluated by qPCR for expression of the -catenin downstream targets
Axin2 and Lef1 in both WT (n  4) and APC KO mice (n  4). Individual data
points represent expression in individual adrenal glands; dashed lines repre-
sent the mean of all adrenal glands evaluated for a given genotype. The mean
WT levels were set equal to 1, and expression was normalized to -actin. Levels
of both Axin2 and Lef1 were elevated approximately twofold in APC KO mice
(P  0.018 and P  0.042, respectively, one-tailed t-test on CT). C: Histolog-
ical comparison of adrenal glands from 15-week-oldWT or APC KOmice. Tissue
sections were subjected to H&E staining or to IHC. Representative sections are
shown. D: Immunofluorescent costaining with -catenin (red) and TH (green)
or -catenin (red) and Sf1 (green). Cells staining red with green nuclei are
Sf1-expressing cells with cytoplasmic -catenin, and those with yellow nuclei
are Sf1-expressing cells with nuclear -catenin. Original magnification: 100
(C); 200 (D).
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AJP September 2012, Vol. 181, No. 3space. In stark contrast, the APC KO adrenal displays
an inner region that is invaded with cells expressing
cytoplasmic/nuclear -catenin but not TH. TH-express-
ing cells of the medulla are distinct and clustered in
small islands. The -catenin-expressing aberrant cells
also expressed Sf1, in the presence of either nuclear or
cytoplasmic -catenin (Figure 3D).
Both -catenin and Dax1 have been implicated in
adrenocortical progenitor cell maintenance and are
normally expressed only in cells of the subcapsular
zone.8,49,50 In the APC KO mouse adrenal, however,
both -catenin and Dax1 are expressed in the aberrant
cells (Figure 3C), suggesting that these cells have a
phenotype similar to subcapsular cells.51–54 Addition-
ally, cells positive for -catenin immunoreactivity are
found sporadically and centripetally throughout the
cortex. The X/fetal zone, marked by the expression of
20-hydroxysteroid dehydrogenase (20-Hsd), lies at
the corticomedullary boundary,55 In female mice, IHC
revealed no difference in the expression pattern of
20-Hsd, suggesting that the X-zone is not affected
(Figure 3C). These data show that knock out of Apc in
mouse adrenocortical cells results in stabilized active
-catenin and the appearance of aberrant cells primar-
ily in the inner region of the gland.
H&E SF
WT
APC KO
APC-BCAT KO
WT 15 W
H&E
β-catenin
A     APC KO
B     Rescue
6 Weeks
Figure 4. Conditional knock out of Apc in mice leads to -catenin-
immunohistochemical staining for -catenin in adrenal glands from a 30-
age. APC KO mice exhibit adrenal hyperplasia that increases with age and
primarily in the inner region of the gland, although a few aberrant cells
were harvested from 6-week-old WT, APC KO, and APC-BCAT KO mice.
APC-BCAT KO mice display staining characteristics similar to those of WT mi
H&E); 100 (A, -catenin; B).Conditional Knock-Out of Apc Leads to Adrenal
Hyperplasia and Adenomas
Because stabilized -catenin correlates with a poor clinical
outcome in ACC patients and because data from APC KO
mice reveal that increased -catenin activity leads to aber-
rant adrenal cells as early as 15 weeks after birth, it was
important to determine whether these APC KO mice would
also develop adrenal tumors. To this end, we analyzed
adrenal glands from APCKOmice at 6, 15, 30, 45, and45
weeks of age. As early as 6 weeks, the adrenal glands from
APC KO mice began to display aberrant -catenin staining
and cortical hyperplasia identifiable on histological analysis
(Figure 4A); however, no adrenocortical tumors were found
in mice younger than 30 weeks of age. In some mice, by 45
weeks and later hyperplasia had progressed to the forma-
tion of microscopic adenomas, visible only on histological
examination (Figure 4A), and macroscopic adenomas visi-
ble to the naked eye. Quantitation of this progression is
discussed in more detail below.
Adrenocortical Dysplasia in APC KO Mice Is
Dependent on -Catenin Expression
Apc has biological functions independent of Wnt-medi-
ated -catenin degradation.56 To confirm that the pheno-
TH β-catenin
30 Weeks 45 Weeks >45 Weeks
ent adrenal hyperplasia and adenomas. A: Histological analysis and
ld WT mouse and from APC KO mice at 6, 15, 30, 45, and 45 weeks of
evelop adenomas at later ages. Abnormal -catenin expression is evident
throughout the cortex. B: Rescue of APC KO phenotype. Adrenal glands
ining and IHC for Sf1, TH, and -catenin were performed. Adrenals from1
eeks
depend
week-o
some d
appear
H&E stace and unlike those of APC KO mice. Original magnification: 40 (A,
mice, in
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AJP September 2012, Vol. 181, No. 3type we observed in our mouse model is mediated by
activated -catenin, we generated mice harboring sto-
chastic mutations of both Apc and Ctnnb1 in Sf1-express-
ing adrenocortical cells (APC-BCAT KO). The breeding
scheme is presented in Supplemental Figure S1C (avail-
able at http://ajp.amjpathol.org). If adrenocortical dyspla-
sia is -catenin-dependent, loss of Ctnnb1 would be ex-
pected to lead to genetic rescue of the phenotype
described in the APC KO mouse. When we examined
the adrenal glands from the adult APC-BCAT KO mice,
we observed a complete absence of the aberrant cells in
the inner space (Figure 4B). Evaluation of Sf1 and TH
expression by IHC revealed a clear delineation between
the adrenal cortex and the medulla in the APC-BCAT KO
mice (Figure 4B). Moreover, cytoplasmic/nuclear -catenin
accumulation was not detected in either the adrenal cortex
or the medulla (Figure 4B). These results confirm that loss of
-catenin prevents the formation of the aberrant cells and
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Figure 5. IGF2 and Igf2 expression is elevated in human ACCs and in mice w
samples from ACA and ACC using microarray data from the UMHS cohort (G
normal samples) (A) and by qPCR of individual human samples from the USP
levels were dramatically elevated in ACCs in both cohorts. No association o
determination of Igf2 levels in adrenals from one Cre control mouse (WT),
Igf2 mRNA was elevated dramatically in the macroscopic adenoma.D: qPCR d
n  4). Igf2 levels were elevated approximately twofold in H19DMD mice
of each group. E:Whole adrenal gland lysates were analyzed by immunoblot
Elevated levels of p-Akt in H19DMD (Cre) mice, relative to that in Cre
replicates (four different mice of each genotype) with similar results.adrenocortical dysplasia seen in APC KO mice, demon-strating that the phenotype of APC KO mice is mediated by
activated -catenin.
Elevated IGF2 Expression in Human ACCs and
Mouse Tumors
Alterations in the 11p15.5 locus have been reported in
many studies of ACC and, as we and others have re-
ported, IGF2 is the most highly up-regulated gene ob-
served in human ACC samples.19,21,26,57,58 Quantitation
of the microarray data from the UMHS cohort demon-
strated that IGF2 levels were elevated 7- to 200-fold,
relative to normal adrenal gland IGF2 levels, in 85% (28/
33) of the ACCs (Figures 2 and 5A). In that cohort, only 1
of 22 ACAs (4.5%) exhibited similarly elevated IGF2 lev-
els (7.8-fold greater than normal). Comparison of IGF2
mRNA levels between groups defined by -catenin sta-
tus (Bcat versus Bcat) failed to demonstrate an associ-
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KO with hyperplasia, and one APC KO with a large macroscopic adenoma.
ation of Igf2 levels in Cre control mice (n 3) and in H19DMDmice (Cre;
05, one-tailed t-test on CT). Horizontal bars represent the mean value
phosphorylated Akt at Ser473 and total Akt, with -actin as a loading control.
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AJP September 2012, Vol. 181, No. 3either ACA or ACC. The USP cohort showed a similar pat-
tern; qPCR analysis revealed 9/11 (82%) ACCs tested have
IGF2 levels 25- to 300-fold above normal adrenal gland
IGF2 levels. Interestingly, 1/12 (8%) ACAs exhibited
an IGF2 level 200-fold greater than normal (Figure 5B).
Similar to the UMHS cohort, -catenin status was inde-
pendent of IGF2 levels. In light of these data, we exam-
ined Igf2mRNA levels in the largest macroscopic adrenal
adenoma observed in the APC KO mice (Weiss score 
2). This macroscopic adenoma had approximately 10-fold
higher Igf2 expression, compared with a normal (Cre/Ap-
cloxP/) or with an APC KO (Cre/ApcloxP/loxP) that displayed
hyperplasia but no gross tumor formation (Figure 5C).
Loss of Imprinting at the IGF2/H19 Differentially
Methylated Domain by Itself Does Not Induce
Tumor Formation in Mice
Transactivation of endogenousmouse Igf2 results in a BWS-
like syndrome, and postnatal overexpression of mouse Igf2
results in adrenocortical hyperplasia.59–61 In addition, given
that most human ACCs and the large macroscopic ade-
noma from the APCKOmouse displayed elevated IGF2 and
Igf2 expression, we set out to determine whether Igf2 over-
expression alone could induce adrenal tumor formation, as
occasionally occurs in BWS. To test this hypothesis, we
used the conditional Igf2/H19 loss-of-imprinting mouse
strain.33 The original characterization of this mutant strain
demonstrated that the DMD is necessary for maternal allele
silencing, allowing Igf2 expression only from the paternal
allele.33 Maternally inherited deletion of the DMD leads to
additional expression of Igf2 from the maternal allele, result-
ing in approximately twofold greater expression.33 To char-
acterize the effects of loss of imprinting of the Igf2/H19
region in the adrenal cortex, we bred female H19lxDMD/lxDMD
mice with male Sf1-Cre mice to obtain progeny with ex-
cision of the maternally inherited DMD stochastically in
Sf1-expressing cells (H19DMD). A breeding scheme is
presented in Supplemental Figure S2A (available at
http://ajp.amjpathol.org). Analysis by qPCR of mRNA from
WT (n  3) and H19DMD (n  4) mouse adrenal glands
confirmed Igf2 expression to be twofold greater in
H19DMD mice than in control animals (P  0.005; Figure
5D). Active Igf2 signaling through its membrane-bound
receptor (Igf1r) can lead to phosphorylation and
thereby activation of Akt, a kinase involved in cell
growth and proliferation (among other downstream ef-
fects).18 Immunoblotting of whole adrenal gland lysates
from H19DMD mice (n  5, WT; n  4, H19DMD) dem-
onstrated the expected increase in p-AktSer473 (Figure
5E). This result, in the absence of an increase in overall
Akt levels, confirms elevated Igf2 signaling.
Having established that we could achieve the loss of
genetic imprinting, we set out to characterize the effects
of Igf2 overexpression in the adrenal cortex. The histo-
logical architecture of adrenal glands from 15-week-old
H19DMD mice shows minor differences from littermate
controls, as determined by H&E staining (see Supple-
mental Figure S5 at http://ajp.amjpathol.org). We allowed
mice to age, and evaluated adrenal gland histology at 30,45, and 45 weeks with similar results. Furthermore,
even at 45 weeks of age the H19DMD mice exhibited
no evidence of hyperplasia or tumor formation. These
data suggest that loss of imprinting through the Igf2/H19
DMD is not sufficient for tumor formation.
Loss of Apc and Overexpression of Igf2 in
Combination Accelerate Tumor Formation
in Mice
To model the dual-hit phenomenon of Apc loss and ele-
vated Igf2 expression, we crossed the APC KO mice with
the H19DMD mice to obtain APC KO-H19DMD. The
breeding schemes were as detailed under Materials and
Methods and presented in Supplemental Figure S2B
(available at http://ajp.amjpathol.org). APC KO-H19DMD
mice were evaluated on the basis of total adrenal mass,
histology, and tumor formation at 15, 30, 45, and 45
weeks of age and were compared with the APC KO and
H19DMD single-mutation mouse models.
For each mouse, the sum of the mass of both adrenal
glands was measured, and fit to an analysis of variance
model with separate means for 32 groups of mice defined
by four age groups (15, 30, 45, and 45 weeks, respec-
tively), the two sexes, and four genetic classes (APC KO,
H19DMD, APC KO-H19DMD, and Cre littermates), and
pairwise contrasts were performed. Two adrenal glands
displayed extraordinarily large tumors (one male APC KO
and one female APC KO-H19DMD mouse). Adrenal
masses of each mouse, including these two outliers, are
presented in Supplemental Figure S6 (available at http://
ajp.amjpathol.org). While keeping these exceptional tu-
mors in mind, we examined differences in the adrenal
mass data even when these samples were excluded. In
female mice, adrenal mass did not significantly increase
between 15 and 45 weeks of age and did not differ
Figure 6. Total adrenal mass increases more rapidly in APC KO-H19DMD
mice, compared with APC KO mice. Adrenal glands were harvested from
mice of the indicated ages and weighed individually. The sum of the two
adrenal gland masses for each mouse was measured and fit to an analysis of
variance model with separate means for 32 groups of mice, defined by four
age groups (15, 30, 45, and 45 weeks), the two sexes, and four genetic
classes: H19DDMD (green), APC KO (blue), APC KO-H19DDMD (red), and
control (yellow). Pairs of groups were compared with F tests for pairwise
contrasts. Female mice (A) exhibited no significant differences; in male mice
(B), significant differences appeared from 30 weeks of age. Data are ex-
pressed as means SD. *P 5.7 105, **P 7.9 105, and ***P 0.012
APC KO versus H19DMD; †P  0.0023, ††P  4.5  107, and †††P  6.7 
108 APC KO-H19DMD versus H19DMD; and ‡P  0.040 APC KO versus
APC KO-H19DMD.between mouse models (Figure 6A). In males, H19DMD
ll mode
chi-squ
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ever, in male APC KO and APC KO-H19DMD mice the
adrenal masses increased between 15 and45 weeks of
age (Figure 6B). Total adrenal masses of male APC KO
mice were larger, relative to those of H19DMD male mice,
by 30 weeks (P  5.7  105) and remained larger at 45
weeks (P  7.8  105) and beyond 45 weeks (P 
0.012). In male APC KO-H19DMD mice, total adrenal
mass was significantly greater than for H19DMD mice by
30 weeks (P  0.002) and remained greater at 45 weeks
(P  4.45  107) and beyond 45 weeks (P  6.7 
108). In addition, the male APC KO-H19DMD mice ex-
hibited significantly larger total adrenal masses than the
APC KO male mice at 45 weeks of age (P  0.04; Figure
6B). In summary, statistically significant increases in total
adrenal masses were observed in male mice with the ge-
netic loss of both Apc and the Igf2/H19 DMD region.
To supplement the adrenal mass data, we measured
cell proliferation in adrenals from 45-week-old mice.
Most adrenals from H19DMD and control mice displayed
a basal level of proliferation (1% of cells per adrenal)
(Table 5). All adrenals from APC KO-H19DMD mice dis-
played an increased number of proliferating cells, com-
pared with control adrenals, whereas 67% of APC KO
mice had adrenals with Ki-67 staining in 1% of cells.
Furthermore, adrenals from multiple APC KO and APC
KO-H19DMD mice presented with accelerated organ
growth (5% of Ki-67-positive cells per adrenal; P 
0.0009 Mantel-Haenszel 2 test of linear association be-
tween all models; Table 5). However, the difference in
Ki-67 staining between APC KO and APC KO-H19DMD
mice did not reach statistical significance (P  0.18).
As adrenal glands were harvested, it became appar-
ent that adrenal tumors were present in the older APC KO
and APC KO-H19DMD mice. Furthermore, in approxi-
mately 40% (4 of 10) of mice with tumors, both adrenals
were visibly enlarged. Therefore, a single pathologist not
directly involved in the animal studies (T.J.G.) did a blind-
study of sections from each of these adrenal glands and
classified them according to guidelines similar to those
used for humans (Figure 7, A–C). The histology of the ad-
renal gland was classified as normal, hyperplastic, micro-
scopic adenoma, macroscopic adenoma, or carcinoma (tu-
mors with mitotic figures). By these criteria, H19DMDmice
displayed normal adrenal glands at all ages examined
(Table 6), as did Cre controls (data not shown). All
adrenal glands from APC KO mice evaluated at 15 weeks
were hyperplastic, and a shift toward microscopic ade-
Table 5. Ki-67 Staining in Mouse Models of Adrenal Tumors
Mouse model*
Tumors with given p
1% 1%–5%
Control (Cre) 4 2
H19DMD 6 2
APC KO 5 6
APC KO-H19DMD† 0 10
*Mantel-Haenszel chi-square analysis of linear association between a
†Comparison of APC KO and APC KO-H19DMD by Mantel-Haenszelnomas was detected by 45 weeks, although adrenalslacking histological changes were still found (Figure 8A
and Table 6). Macroscopic adenomas were not detected
in APC KO mice until after 45 weeks of age, and no
carcinomas were detected. Using the Mantel-Haenszel
2 test of linear association, we found significantly worse
histological findings for APC KO mice, compared with
H19DMD mice (P  0.004, two-sided test). Like the APC
KO mice, all APC KO-H19DMD mice displayed adreno-
cortical hyperplasia by 15 weeks of age. In contrast, at 45
weeks of age, microscopic and/or macroscopic adeno-
mas were present in adrenal glands from 33.3% (4 of 12)
of APC KO-H19DMD mice, with a single carcinoma evi-
dent after 45 weeks (Figure 8B and Table 6). APC KO-
H19DMDmice also fared worse, compared with H19DMD
mice (P  0.0005, 2 test of linear association); however,
statistical significance between tumor formation in APC
KO and APC KO-H19DMD mice reached only a value of
P  0.047, which may reflect too small a sample.
Under Weiss parameters, a single macroscopic ade-
noma from an APC KO mouse was scored as high as 2,
consistent with a benign lesion, whereas a tumor from
age of Ki-67 cells (no.)
Total adrenals
evaluated5%–10% 10–20%
0 0 6
0 0 8
3 1 15
2 2 14
ls: P  0.0009.
are: P  0.18.
Cre (-) Cre (+) Right Left Halves
Macroscopic adenoma
Hyperplasia/Microscopic adenomaNormalA B
C
Figure 7. Combined loss of Apc and loss of imprinting at the DMD of the
Igf2/H19 region results in tumor formation in mice. Images (H&E) shown are
representative of normal adrenal glands from a 45-week-old normal mouse
(A) and a 60-week-old APC KO mouse demonstrating hyperplasia to ade-
noma formation (B). C: Macroscopic adenomas were also found in APC KO
and APC KO-H19DMD mice. Gross anatomy of adrenal glands from 45-
week-old WT (Cre) and APC KO-H19DMD (Cre) mice are shown. Forercentscale (C), black lines are spaced 1 mm apart. Original magnification: 40 (A,
upper row); 100 (A, lower row).
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indicative of carcinoma (Figure 8, C and D). Given our
human data and the qPCR data from APC KO mice, we
measured the -catenin activity and Igf2 mRNA expres-
sion levels in these two tumors. Both tumors displayed
elevated -catenin signaling, including up-regulation of
the downstream target gene Axin2 (Figure 3B). Com-
pared with adrenals from control (Cre) mice, the Weiss
2 tumor from an APC KO mouse showed dramatically
increased Igf2mRNA levels (Figure 5C). Surprisingly, Igf2
mRNA expression in the Weiss 3 tumor harvested from an
APC KO-H19DMD was actually decreased, compared
with Cre controls (data not shown). This unexplained
result may indicate that as yet unidentified additional
mutations or alterations in gene regulation are involved in
this unique tumor. Nevertheless, in total, our data indicate
that the combination of activated -catenin and loss of
imprinting of the Igf2/H19 locus (loss of Apc and the
Igf2/H19 DMD) shifts the tumor spectrum in the adrenal
cortex to earlier and more aggressive neoplasia.
Discussion
Adrenocortical carcinoma is an aggressive and often le-
thal disease, largely because it typically escapes diag-
nosis until it has already progressed to a late stage and
because its inherent chemoresistance renders most cy-
totoxic therapies ineffective. The relative rarity of ACC
hinders efforts to understand its etiology; few clinical
samples are available for laboratory studies, and ACC
cell lines are notoriously difficult to establish. These facts
Table 6. Prevalence of Hyperplasia and Tumors in Mouse Mode
Age, sample size, and findings H19DMD [no. (%)]
15 weeks
Total examined 3
Normal 3 (100)
Hyperplasia 0
Microscopic adenoma 0
Macroscopic adenoma 0
Carcinoma 0
30 weeks
Total examined 3
Normal 3 (100)
Hyperplasia 0
Microscopic adenoma 0
Macroscopic adenoma 0
Carcinoma 0
45 weeks
Total examined 6
Normal 6 (100)
Hyperplasia 0
Microscopic adenoma 0
Macroscopic adenoma 0
Carcinoma 0
45 Weeks
Total examined 8
Normal 8 (100)
Hyperplasia 0
Microscopic adenoma 0
Macroscopic adenoma 0
Carcinoma 0provide impetus for the generation of better mouse mod-els of ACC, to further understanding of underlying mech-
anisms and to develop effective targeted therapies. In the
present study, we modeled adrenocortical carcinoma
through stabilization of -catenin (via loss of Apc) and
elevation of Igf2 levels (via loss of Igf2/H19 DMD) in mice,
providing a tool to study the contribution of multiple on-
cogenic mutations to ACC development.
Although adrenocortical tumors may manifest in the
context of a familial cancer syndrome, such as FAP or
BWS, the majority of ACCs arise sporadically.62,63 Ap-
proximately 13% of FAP patients, characterized by mu-
tations in APC and elevated Wnt/-catenin signaling, de-
velop adrenocortical tumors; however, these tumors
rarely progress to ACC.64–66 Similarly, BWS patients,
with genetic mutations in the 11p15.5 locus and a resul-
tant increase in IGF2 expression, develop adrenocortical
hyperplasia but rarely ACC, which accounts for only 7%
of the malignancies found in this syndrome.6 In contrast,
in sporadic ACC, IGF2 is up-regulated in 80% to 90% of
cases but is increased in only approximately 5% of
ACAs.19–21,23,47,67 Despite anecdotal clinical reports, it
remains unclear how frequently carcinomas of the adre-
nal cortex arise from pre-existing benign neoplasms.40
Recent molecular and clinical studies, however, increas-
ingly support a multistep model whereby normal adrenal
glands become hyperplastic and progress to ACC.68,69
Differences in size between ACA and ACC tumors and
the presence of aggressive ACCs embedded within ACA
tissue also support a multistep progression,70–72 consis-
tent with our understanding of most carcinoma types.
Previous studies of large human cohorts have revealed
APC KO [no. (%)] APC KO-H19DMD [no. (%)]
10 7
0 0
10 (100) 7 (100)
0 0
0 0
0 0
8 9
0 0
8 (100) 9 (100)
0 0
0 0
0 0
6 12
0 1 (8.3)
5 (83.3) 7 (58.3)
1 (16.7) 1 (8.3)
0 3 (25)
0 0
15 14
3 (20) 0
8 (53.3) 8 (57.1)
2 (13.3) 1 (7.1)
2 (13.3) 4 (28.6)
0 1 (7.1)lsthat the WNT/-catenin signaling pathway is up-regu-
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UMHS and USP data in the present study revealed exon
3 mutations in 21.7% (10 of 46 tested) of ACAs and
22.6% (7 of 31 tested) of ACCs, similar to previously
reported frequency of CTNNB1 mutations in ACAs (27%)
and ACCs (16% to 31%).9,12 A missense mutation in one
of the phosphorylation sites, codon 45 of exon 3, was the
most frequent genetic alteration of CTNNB1. CTNNB1
mutations have been correlated with abnormal
-catenin localization by classical IHC, and as many as
39% of ACAs and 77% of ACCs have abnormal cyto-
plasmic and nuclear accumulation of -catenin.9–12,37
The present study revealed that abnormal cytoplasmic or
nuclear -catenin staining was observed in 24.1% of the
adenomas and 30% of the carcinomas. As expected,
most tumors with CTNNB1 mutations also had abnormal
-catenin staining. Interestingly, four ACA samples with
mutations did not exhibit obvious abnormal staining, an
observation consistent with the array results discussed
below. Nuclear staining is not always accompanied by
CTNNB1 mutations, indicating that other mutations not
examined here may also contribute to tumorigenesis.
Consistent with previous reports, we observed that
abnormal or nuclear -catenin accumulation in ACC is
associated with a dismal prognosis.12,37 In the present
study, however, when we combined stage and grade
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Figure 8. APC KO and APC KO-H19DMD mice develop tumors of increased
severity. A and B: Tumor types present in APC KO mice and APC KO-
H19DMD mice at 45 and 45 weeks of age. C: Adrenal (H&E) of a 48-week-
old APC KO mouse. The APC KO mice exhibit some microscopic and
macroscopic adenomas but no tumors with a Weiss score of 2. D: Adrenal
(H&E) of a 55-week-old APC KO-H19DMD mouse with adrenocortical car-
cinoma. H&E staining was performed on adrenal glands harvested from mice
at 15, 30, 45, and 45 weeks of age. H&E-stained sections of all available
adrenal glands from WT (Cre controls), H19DMD, APC KO, and APC
KO-H19DMD mice were evaluated by a single pathologist (T.J.G.) and
categorized as normal or as having hyperplasia, microscopic adenoma, mac-
roscopic adenoma, or carcinoma. Representative images are shown in Figure
7, and the data are summarized in Table 6. Original magnification, 200.
NTF, no tumors found.with -catenin status to evaluate prognosis, we found that-catenin status does not improve predictive power. This
is not surprising, given that abnormal -catenin is prev-
alent in high-grade ACC. Thus, measuring cell prolifera-
tion directly can capture much of the influence of
-catenin on survival, as well as increases in proliferation
due to some other mutations, and might therefore be a
better predictor of outcome than -catenin status
alone.39 In addition, we attempted to correlate -catenin
status with tumor functionality. Significantly, in the UMHS
cohort, ACAs with abnormal -catenin are less likely to be
hormone secreting (37.5%; 3 of 8 tested), whereas in
ACC with abnormal -catenin status are more likely to be
hormone secreting (92% or 11 of 12 samples). Similar
results were not found for the USP cohort. More studies
are required to determine the relationships among
-catenin, functionality, and malignancy.
Using our published array data, we compared gene
expression in adrenocortical tumors with membranous
-catenin staining with the gene expression of adreno-
cortical tumors with cytoplasmic/nuclear -catenin stain-
ing. This approach revealed that the presence of abnor-
mal -catenin staining in ACC (and not so evident in
ACA) corresponded to differential expression of a signif-
icant number of genes. ACCs with nuclear or cytoplasmic
-catenin staining had increased transcripts for genes
involved in cell division, p53 function, and Wnt signaling,
consistent with the finding here and elsewhere12,39 that
Bcat ACCs have a higher mitotic rate and may confer an
advantage for growth in these tumors. The genes that
had increased expression in Bcat ACC contained an
abundance of TCF/LEF transcription factor binding sites
in their promoters, suggesting that nuclear -catenin is
stabilized, transcriptionally active, and contributing to tu-
morigenesis. However, our array data demonstrate that
WNT pathway activation has transcriptionally distinct
consequences in ACA and ACC, suggesting that WNT
activation in benign and malignant settings is not func-
tionally equivalent. It is possible that this reflects differ-
ences in their genetic milieu, such as the dramatically
up-regulated expression of IGF2 observed in most human
ACCs but not ACAs. Alternatively, it is possible that
-catenin mutation in ACA is subclonal, manifesting as
nuclear -catenin in only a small percentage of cells,
which is consistent with our observation that nuclear
-catenin immunoreactivity is less intense in these tumors
and present in scattered isolated cells (personal obser-
vation, T.J.G.).
In a separate study, Berthon et al40 found that consti-
tutively active -catenin can act as an adrenocortical
oncogene to induce adrenal hyperplasia and tumor for-
mation. In their mouse model, exon 3 was mutated in cells
in which Ark1b7 is expressed (in the zona fasciculata) but
not in cells in which -catenin is normally expressed (in
the subcapsular region, including the adrenocortical
stem/progenitor cells and zona glomerulosa), making the
physiological interpretation difficult. In the Berthon et al40
study, although samples from mice up to 10 months of
age displayed abnormalities in adrenal gland architec-
ture, the adenomas present were graded with a Weiss
score of 2. However, after 17 months of age (	68
weeks), adrenal glands from 2 of 17 animals analyzed
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the present study, we have attempted to demonstrate the
importance of -catenin stabilization in adrenal tumori-
genesis through the loss of Apc in Sf1-expressing cells,
including those cells in which -catenin is normally ex-
pressed. In our model, we detected hyperplasia that pro-
gressed to microscopic adenomas and macroscopic ad-
enomas as early as 15 weeks of age. Loss of Apc led to
the biochemical activation of -catenin and the presence
of Sf1-positive, -catenin-positive cells primarily in the
inner region of the gland. Because loss of Apc might be
predicted to lead to other effects unrelated to -catenin,
we attempted to rescue the APC KO phenotype by deleting
Ctnnb1. Loss of both Ctnnb1 and Apc led to formation of
adrenal glands that resembled WT glands, confirming
that tumor formation was dependent on stabilization of
-catenin.
Having established a functional model of adrenocorti-
cal tumorigenesis, we wanted to explore the combinato-
rial effect of two mutations known to participate in this
process. IGF2 expression is dramatically elevated in most
human ACCs. We therefore chose to model the com-
bined loss of Apc and up-regulation of Igf2. The H19DMD
model led to an approximate twofold increase in Igf2
levels and activation of Igf signaling. This is in accord
with expression of Igf2 from both maternal and paternal
alleles and the modest two- to threefold increase in most
human tumors displaying loss of imprinting, but less than
seen in most patients with ACC.73 Consistent with reports
from previous models of Igf2 overexpression,60,61,74 we
did not observe tumors in aged H19DMD mice.
Our main objective was to determine how this loss of
imprinting could cooperate with loss of Apc to contribute
to carcinogenesis. Interaction between Apc and Igf2 in
tumor formation is supported by mouse modeling studies
of intestinal tumorigenesis in whichMinmice (harboring a
mutation in Apc and a mouse model for FAP) were
crossed with mice exhibiting a loss of imprinting at the
Igf2/H19 DMD. Compared with Min mice, mice harboring
both mutations exhibited more intestinal adenomas (2.2-
fold increase in tumor number) of larger size (2.5-fold
increase in tumor surface area).75 In our mouse models,
combined loss of Apc and loss of imprinting at the Igf2
locus resulted in increased adrenal masses and earlier
onset of tumor formation. The explanation for the differ-
ence in effects of these mutations on adrenal masses of
males versus females is unclear, although sex differ-
ences in adrenal development as well as hormonal milieu
may contribute. As in APC KO mice, hyperplasia in APC
KO-H19DMD mice was detected as early as 15 weeks of
age. In contrast to APC KO mice, however, both micro-
scopic and macroscopic adenomas were present in APC
KO-H19DMD by 45 weeks, and one carcinoma was
found after 45 weeks (at 56 weeks of age).
We were somewhat surprised that the percentage of
carcinomas in our model was not higher. We chose the
model of sporadic loss of Apc and the Igf2/H19 DMD
region in adrenocortical cells, because it is a more ac-
curate representation of tumor progression in humans.
Our results could be due in part to the use of the Sf1-Cre
stochastic driver, which results in recombination in only asubset of adrenocortical cells and potentially at different
times in Sf1-expressing cells. In addition, the low pen-
etrance of ACC in patients with germline mutations in the
APC gene in FAP and loss of imprinting in the IGF2 locus
in BWS indicates that additional mutations contribute to
the ultimate manifestation of cancer.6 Indeed, it has been
proposed that human ACCs may harbor as many as 30
mutations or genetic aberrations.6 The largest tumor
found in the APC KO mice was graded Weiss 2 and had
elevated -catenin signaling and distinctly elevated Igf2
expression, whereas the unique Weiss 3 tumor from the
APC KO-H19DMD mouse had elevated -catenin and
Wnt signaling but decreased Igf2 expression. This could
suggest that the enhanced stability of -catenin (or some
other mutated gene product) may preclude expression
from the floxed maternal Igf2/H19 gene locus.
Elimination of the DMD region in the presence of sta-
bilized -catenin may have unintended consequences on
the expression of other transcripts in this complex locus,
including H19, Cdkn1c, and miR-483. Of these tran-
scripts, miR-483 has been shown to be highly expressed
in ACC.76 Indeed, recent studies have shown that
-catenin can transcriptionally activate miR-483 expres-
sion separate from Igf277,78. A few human hepatocarci-
nomas and colorectal cancer samples have displayed
elevated miR-483 levels associated with decreased Igf2
expression.77 Nevertheless, it remains clear that mice
with stabilized -catenin and loss of imprinting at the
Igf2/H19 locus develop more tumors at an earlier age.
Additional studies are required to determine the precise
mechanism by which transcripts from the Igf2/H19 locus,
the expression of Igf2, and stabilization of -catenin in-
teract to accelerate tumor formation.
In summary, we have integrated human clinicopatho-
logic and DNA microarray data with mouse models to
show that, although abnormal activation of either the WNT
or the IGF2 pathway is not sufficient to drive the devel-
opment of carcinomas, the combined dysregulation of
both is a major contributor to ACC. These results provide
a model in which dysregulation of one pathway may
result in adrenal hyperplasia, but accumulation of a sec-
ond or multiple alterations is necessary for tumorigenesis.
Further studies will be required to uncover the additional
genetic and epigenetic events that contribute to this
highly aggressive and deadly disease.
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